CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma

Overview Investor newsPipeline Innovative Medicine pipelineDevelopment pipelineNovel therapies2026 Key eventsPatent table Financials Quarterly resultsAnnual reportsSEC filingsInvestor fact sheet Events & presentationsStock info Stock quoteStock chartHistorical stock quoteInvestment calculatorDividend historyStock split information Governance Corporate governance overview2026 Annual Meeting of ShareholdersBoard of DirectorsExecutive CommitteeESG resources2025 Health for Humanity Report2024 Janssen Transparency Report Resources Investor FAQsInformation request formInvestor email alertsInvestor contacts Latest news Our company Careers Investors Media center Search query Discover J&J News Details Overview Investor newsPipelineFinancialsEvents & presentationsStock infoGovernanceResources jnj.comInvestor relationsInvestor news